NIKKEI 225
38,659.45 -44.06 (-0.11%) HANG SENG
18,478.55 +1.75 (+0.01%) CRUDE OIL
75.59 +0.04 (+0.05%) GOLD FUTURES
2,390.00 -0.90 (-0.04%) DOW
38,886.17 +78.84 (+0.20%) Bitcoin GBP
55,280.75 -356.16 (-0.64%)
AstraZeneca PLC (AZN.L)
| Previous close | 12,516.00 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,417,431 |
| Market cap | 195.178B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 39.72 |
| EPS (TTM) | 3.17 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 2.28 (1.82%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 131.68 |
PR NewswireI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.
Fool.co.uk2 superb FTSE 100 stocks I’d buy for a SIPP and hold for a decade
This Fool highlights a pair of excellent blue-chip stocks that he'd buy today and tuck away in a SIPP portfolio for the long run. The post 2 superb FTSE 100 stocks I’d buy for a SIPP and hold for a decade appeared first on The Motley Fool UK.
PR NewswireAbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its first time in human investigator-initiated trial (IIT) of C-CAR031 in connection with the Company's oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation shared data indicati
